Search

Your search keyword '"Zucchetti, Elisa"' showing total 20 results
Start Over Author "Zucchetti, Elisa" Publication Year Range Last 50 years
20 results on '"Zucchetti, Elisa"'

4. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO)

Author

Candoni, Anna, Rambaldi, Alessandro, Fanin, Renato, Velardi, Andrea, Arcese, William, Ciceri, Fabio, Lazzarotto, Davide, Lussana, Federico, Olivieri, Jacopo, Grillo, Giovanni, Parma, Matteo, Bruno, Benedetto, Sora, Federica, Bernasconi, Paolo, Saccardi, Riccardo, Foà, Robin, Sessa, Mariarosa, Bresciani, Paola, Giglio, Fabio, Picardi, Alessandra, Busca, Alessandro, Sica, Simona, Perruccio, Katia, Zucchetti, Elisa, Diral, Elisa, Iori, Anna Paola, Colombo, Anna Amelia, Tringali, Stefano, Santarone, Stella, Irrera, Giuseppe, Mancini, Stefano, Zallio, Francesco, Malagola, Michele, Albano, Francesco, Carella, Angelo Michele, Olivieri, Attilio, Tecchio, Cristina, Dominietto, Alida, Vacca, Adriana, Sorasio, Roberto, Orciuolo, Enrico, Risitano, Antonio Maria, Leotta, Salvatore, Cortelezzi, Agostino, Mammoliti, Sonia, Oldani, Elena, and Bonifazi, Francesca

Published
2019
Full Text
View/download PDF

5. The Role of Serum IgG Precipitins against Six Typical Organic Antigens Involved in Hypersensitivity Pneumonitis: A 10-Year Retrospective Study of a Referral Interstitial Lung Disease Centre.

Author

Intra, Jari, Biffi, Alice, Basta, Francesca, Delfini, Cristina, Novati, Nicoletta, Zucchetti, Elisa, Luppi, Fabrizio, and Casati, Marco

Subjects
INTERSTITIAL lung diseases, HYPERSENSITIVITY pneumonitis, IMMUNOGLOBULIN G, ANTIGENS, ALTERNARIA alternata, PENICILLIUM chrysogenum
Abstract

Hypersensitivity pneumonitis (HP) represents the third common interstitial lung disease caused by an exaggerated immune response following the inhalation of organic and/or chemical environmental antigens. The aim of this study was to determine the cut-off values of specific IgG antibodies (named precipitins) and their association with clinical data in the diagnosis of HP. In this 10-year retrospective study, the IgG concentrations against six antigens, Penicillium chrysogenum/notatum, Aspergillus fumigatus, Alternaria alternata, Aspergillus niger, Micropolyspora faeni, and pigeon droppings, were retrieved. The controlled group was made of 1516 healthy subjects without diagnosis of lung pathologies, while the case group consisted of 54 individuals affected by HP. Considering all six IgG antibodies together and the 97.5% percentiles determined in the control group, 30 of 54 subjects (56%) had one or more positive precipitins. In these patients, the major frequencies found were IgG antibodies against pigeon droppings, followed by Penicillium chrysogenum/notatum and Aspergillus niger. Although the sensitivity of serum precipitins depends on the population enrolled and the method used, the cut-off values determined in this study can be a valuable tool for clinicians in the diagnosis of HP, in eliminating the antigens responsible from the environment, and in establishing more specific IgG panels. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Author

Girmenia, Corrado, Raiola, Anna Maria, Piciocchi, Alfonso, Algarotti, Alessandra, Stanzani, Marta, Cudillo, Laura, Pecoraro, Clara, Guidi, Stefano, Iori, Anna Paola, Montante, Barbara, Chiusolo, Patrizia, Lanino, Edoardo, Carella, Angelo Michele, Zucchetti, Elisa, Bruno, Benedetto, Irrera, Giuseppe, Patriarca, Francesca, Baronciani, Donatella, Musso, Maurizio, Prete, Arcangelo, Risitano, Antonio Maria, Russo, Domenico, Mordini, Nicola, Pastore, Domenico, Vacca, Adriana, Onida, Francesco, Falcioni, Sadia, Pisapia, Giovanni, Milone, Giuseppe, Vallisa, Daniele, Olivieri, Attilio, Bonini, Alessandro, Castagnola, Elio, Sica, Simona, Majolino, Ignazio, Bosi, Alberto, Busca, Alessandro, Arcese, William, Bandini, Giuseppe, Bacigalupo, Andrea, Rambaldi, Alessandro, and Locasciulli, Anna

Published
2014
Full Text
View/download PDF

10. Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience

Author

Riva, Marta, primary, Rizzo, Lorenzo, additional, Mancini, Valentina, additional, Greco, Rosa, additional, Bertani, Giambattista, additional, Zucchetti, Elisa, additional, Diral, Elisa, additional, Nichelatti, Michele, additional, Veronese, Silvio Marco, additional, Grillo, Giovanni, additional, and Cairoli, Roberto, additional

Published
2020
Full Text
View/download PDF

12. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (Gitmo)

Author

Candoni, Anna, Rambaldi, Alessandro, Fanin, Renato, Velardi, Andrea, Arcese, William, Ciceri, Fabio, Lazzarotto, Davide, Lussana, Federico, Olivieri, Jacopo, Grillo, Giovanni, Parma, Matteo, Bruno, Benedetto, Sora', Federica, Bernasconi, Paolo, Saccardi, Riccardo, Foa, Robin, Sessa, Mariarosa, Bresciani, Paola, Giglio, Fabio, Picardi, Alessandra, Busca, Alessandro, Sica, Simona, Perruccio, Katia, Zucchetti, Elisa, Diral, Elisa, Iori, Anna Paola, Colombo, Anna Amelia, Tringali, Stefano, Santarone, Stella, Irrera, Giuseppe, Mancini, Stefano, Zallio, Francesco, Malagola, Michele, Albano, Francesco, Carella, Angelo Michele, Olivieri, Attilio, Tecchio, Cristina, Dominietto, Alida, Vacca, Adriana, Sorasio, Roberto, Orciuolo, Enrico, Risitano, Antonio Maria, Leotta, Salvatore Nuccio, Cortelezzi, Agostino, Mammoliti, Sonia, Oldani, Elena, Bonifazi, Francesca, Sora, Federica (ORCID:0000-0002-9607-5298), Foà, Robin, Sica, Simona (ORCID:0000-0003-2426-3465), Candoni, Anna, Rambaldi, Alessandro, Fanin, Renato, Velardi, Andrea, Arcese, William, Ciceri, Fabio, Lazzarotto, Davide, Lussana, Federico, Olivieri, Jacopo, Grillo, Giovanni, Parma, Matteo, Bruno, Benedetto, Sora', Federica, Bernasconi, Paolo, Saccardi, Riccardo, Foa, Robin, Sessa, Mariarosa, Bresciani, Paola, Giglio, Fabio, Picardi, Alessandra, Busca, Alessandro, Sica, Simona, Perruccio, Katia, Zucchetti, Elisa, Diral, Elisa, Iori, Anna Paola, Colombo, Anna Amelia, Tringali, Stefano, Santarone, Stella, Irrera, Giuseppe, Mancini, Stefano, Zallio, Francesco, Malagola, Michele, Albano, Francesco, Carella, Angelo Michele, Olivieri, Attilio, Tecchio, Cristina, Dominietto, Alida, Vacca, Adriana, Sorasio, Roberto, Orciuolo, Enrico, Risitano, Antonio Maria, Leotta, Salvatore Nuccio, Cortelezzi, Agostino, Mammoliti, Sonia, Oldani, Elena, Bonifazi, Francesca, Sora, Federica (ORCID:0000-0002-9607-5298), Foà, Robin, and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

PURPOSE: We performed a nationwide registry-based analysis to describe the clinical outcome of adults patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who underwent an allogeneic hematopoietic stem cell transplantation (HSCT) after a TKI-based treatment. PATIENTS AND RESULTS: A total of 441 patients were included in the study. The median age at HSCT was 44 years (range 18-70). All the 441 patients (100%) received TKI before the HSCT (performed between 2005 and 2016). Of these patients, 404 (92%) were in cytologic complete remission (CR), while the remaining 37 (8%) had an active disease at the time of HSCT. Molecular minimal residual disease (MRD) was negative in 147 patients (36%) at the time of HSCT. The donor was unrelated in 46% of cases. The prevalent source of stem cells was peripheral blood (70%). The conditioning regimen was myeloablative in 82% of cases (TBI-based in 50%) and included ATG in 51% of cases. With a median follow-up after HSCT of 39.4 months (range: 1-145), the overall survival (OS) probability at 1, 2 and 5 years was 69.6%, 61.1% and 50.3%, respectively, with a median OS of 62 months. Progression-free survival (PFS) at 1, 2 and 5 years was 60.2%, 52.1% and 43.7%, respectively. OS and PFS were significantly better in patients with CR and MRD-negative at the time of transplant compared with those of patients with CR but MRD-positive (50% OS not reached vs. 36 months, P=0.015; 50% PFS not reached vs. 26 months, P=0.003). The subgroup of MRD-negative patients both at HSCT and at 3 months after HSCT had a better outcome (5 years OS rate 70%). Conversely, the 37 patients who underwent a HSCT with active Ph+ ALL had a median OS and PFS of 7 and 5 months, respectively. The 5 years cumulative incidence of relapse was significantly lower in MRD-negative patients (19.5% vs. 35.4%, P=0.001). The non-relapse mortality (NRM) after 1, 2 and 5 years was 19.1% (95%CI: 15.5-22.9), 20.7% (95%CI: 17-24.7) and 24.1% (9

Published
2019

14. Response of steroid‐refractory chronic graft‐versus‐host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles

Author

Bertani, Giambattista, primary, Santoleri, Luca, additional, Ferri, Ursula, additional, Marenco, Paola, additional, Grillo, Giovanni, additional, Zucchetti, Elisa, additional, Forno, Barbara, additional, Lando, Giuliana, additional, Scarpati, Barbara, additional, Cairoli, Roberto, additional, Rossini, Silvano, additional, and Cesana, Clara, additional

Published
2015
Full Text
View/download PDF

17. Role of Rituximab and Intensification with Autologous Stem Cell Transplantation in Primary Mediastinal B-Cell Lymphoma

Author

Zilioli, Vittorio Ruggero, primary, Rusconi, Chiara, additional, Gabutti, Cristina, additional, Grillo, Giovanni, additional, Zucchetti, Elisa, additional, Meli, Erika, additional, Monti, Alessandro, additional, Greco, Antonino, additional, Caramella, Marianna, additional, Mazzucchelli, Maddalena, additional, Nichelatti, Michele, additional, and Morra, Enrica, additional

Published
2012
Full Text
View/download PDF

19. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO

Author

Simona Sica, Laura Cudillo, Marta Stanzani, Antonio M. Risitano, Barbara Montante, Giovanni Pisapia, Maurizio Musso, Clara Pecoraro, Attilio Olivieri, Alessandro Rambaldi, Angelo Michele Carella, Francesca Patriarca, Alessandro Bonini, Anna Paola Iori, Ignazio Majolino, Adriana Vacca, Giuseppe Irrera, Nicola Mordini, Alberto Bosi, Corrado Girmenia, Giuseppe Milone, Domenico Pastore, Alessandro Busca, Donatella Baronciani, Stefano Guidi, Alessandra Algarotti, Alfonso Piciocchi, Giuseppe Bandini, Elio Castagnola, Patrizia Chiusolo, Andrea Bacigalupo, William Arcese, Benedetto Bruno, Elisa Zucchetti, Francesco Onida, Edoardo Lanino, Anna Maria Raiola, Domenico Russo, Daniele Vallisa, Sadia Falcioni, Arcangelo Prete, Anna Locasciulli, Girmenia, Corrado, Raiola, Anna Maria, Piciocchi, Alfonso, Algarotti, Alessandra, Stanzani, Marta, Cudillo, Laura, Pecoraro, Clara, Guidi, Stefano, Iori, Anna Paola, Montante, Barbara, Chiusolo, Patrizia, Lanino, Edoardo, Carella, Angelo Michele, Zucchetti, Elisa, Bruno, Benedetto, Irrera, Giuseppe, Patriarca, Francesca, Baronciani, Donatella, Musso, Maurizio, Prete, Arcangelo, Risitano, ANTONIO MARIA, Russo, Domenico, Mordini, Nicola, Pastore, Domenico, Vacca, Adriana, Onida, Francesco, Falcioni, Sadia, Pisapia, Giovanni, Milone, Giuseppe, Vallisa, Daniele, Olivieri, Attilio, Bonini, Alessandro, Castagnola, Elio, Sica, Simona, Majolino, Ignazio, Bosi, Alberto, Busca, Alessandro, Arcese, William, Bandini, Giuseppe, Bacigalupo, Andrea, Rambaldi, Alessandro, and Locasciulli, Anna

Subjects
Adult, medicine.medical_specialty, Adolescent, Epidemiology, medicine.medical_treatment, Mycose, Hematopoietic stem cell transplantation, Young Adult, Internal medicine, Allogeneic HSCT, medicine, Humans, Transplantation, Homologous, Cumulative incidence, Prospective Studies, Prospective cohort study, Child, Transplantation, Homologou, Aged, Acute leukemia, Transplantation, Hematology, business.industry, fungal infection, Incidence, Hazard ratio, Hematopoietic Stem Cell Transplantation, Infant, Middle Aged, Surgery, Prospective Studie, surgical procedures, operative, Treatment Outcome, Mycoses, Italy, Cord blood, Child, Preschool, Invasive fungal disease, business, Settore MED/15 - Malattie del Sangue, Human
Abstract

Epidemiologic investigation of invasive fungal diseases (IFDs) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be useful to identify subpopulations who might benefit from targeted treatment strategies. The Gruppo Italiano Trapianto Midollo Osseo (GITMO) prospectively registered data on 1858 consecutive patients undergoing allo-HSCT between 2008 and 2010. Logistic regression analysis was performed to identify risk factors for proven/probable IFD (PP-IFD) during the early (days 0 to 40), late (days 41 to 100), and very late (days 101 to 365) phases after allo-HSCT and to evaluate the impact of PP-IFDs on 1-year overall survival. The cumulative incidence of PP-IFDs was 5.1% at 40 days, 6.7% at 100 days, and 8.8% at 12 months post-transplantation. Multivariate analysis identified the following variables as associated with PP-IFDs: transplant from an unrelated volunteer donor or cord blood, active acute leukemia at the time of transplantation, and an IFD before transplantation in the early phase; transplant from an unrelated volunteer donor or cord blood and grade II-IV acute graft-versus-host disease (GVHD) in the late phase; and grade II-IV acute GVHD and extensive chronic GVHD in the very late phase. The risk for PP-IFD was significantly higher when acute GVHD was followed by chronic GVHD and when acute GVHD occurred in patients undergoing transplantation with grafts from other than matched related donors. The presence of PP-IFD was an independent factor in long-term survival (hazard ratio, 2.90; 95% confidence interval, 2.32 to 3.62; P

Published
2014

20. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.

Author

Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, and Locke FL

Subjects
Antigens, CD19 therapeutic use, Biological Products, Humans, Retrospective Studies, Immune Reconstitution, Immunotherapy, Adoptive
Abstract

CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections may occur. In this single center retrospective study of 85 patients, we characterized immune reconstitution and infections for patients remaining in remission after axi-cel for LBCL. Prolonged cytopenias (those occurring at or after day 30 following infusion) were common with >= grade 3 neutropenia seen in 21/70 (30-0%) patients at day 30 and persisting in 3/31 (9-7%) patients at 1 year. B cells were undetectable in 30/34 (88-2%) patients at day 30, but were detected in 11/19 (57-9%) at 1 year. Median IgG levels reached a nadir at day 180. By contrast, CD4 T cells decreased from baseline and were persistently low with a median CD4 count of 155 cells/μl at 1 year after axi-cel (n=19, range 33 - 269). In total, 23/85 (27-1%) patients received IVIG after axi-cel, and 34/85 (40-0%) received G-CSF. Infections in the first 30 days occurred in 31/85 (36-5%) patients, of which 11/85 (12-9%) required intravenous antibiotics or hospitalization ("severe") and were associated with cytokine release syndrome (CRS), neurotoxicity, tocilizumab use, corticosteroid use, and bridging therapy on univariate analyses. After day 30, 7 severe infections occurred, with no late deaths due to infection. Prolonged cytopenias are common following axi-cel therapy for LBCL and typically recover with time. Most patients experience profound and prolonged CD4 T cell immunosuppression without severe infection.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results